Mandy van Brakel

Mandy van Brakel

Auto-generated profile, based on publicly available information

Mandy van Brakel

Erasmus MC Cancer Institute 4 Department of Medical Oncology Erasmus University Medical Center, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
AKAndre Kunert
Andre Kunert
MBMandy van Brakel
Mandy van Brakel
SSSabine van Steenbergen-Langeveld
Sabine van Steenbergen-Langeveld
MSMarvin da Silva
Marvin da Silva
PCPierre Coulie
Pierre Coulie
RDReno Debets
Reno Debets
Adoptive T cell therapy has shown significant clinical success for patients with advanced melanoma and other tumors. Further development of T cell therapy requires improved strategies to select effective, yet nonself-reactive, TCRs. In this study, we isolated 10 TCR sequences against four MAGE-C2 (MC2) epitopes from melanoma patients who showed clinical responses following vaccination that were accompanied by significant frequencies of anti-MC2 CD8 T cells in blood and tumor without apparent side effects. We introduced these TCRs into T cells, pretreated tumor cells of different histological origins with the epigenetic drugs azacytidine and valproate, and tested tumor and self-reactivities of these TCRs. Pretreatment of tumor cells upregulated MC2 gene expression and enhanced recognition by T cells. In contrast, a panel of normal cell types did not express MC2 mRNA, and similar pretreatment did not result in recognition by MC2-directed T cells. Interestingly, the expression levels of MC2, but not those of CD80, CD86, or programmed death-ligand 1 or 2, correlated with T cell responsiveness. One of the tested TCRs consistently recognized pretreated MC2+ cell lines from melanoma, head and neck, bladder, and triple-negative breast cancers but showed no response to MHC-eluted peptides or peptides highly similar to MC2. We conclude that targeting MC2 Ag, combined with epigenetic drug-enhanced antigenicity, allows for significant and tumor-selective T cell responses.

21 August 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DKDian Kortleve
Dian Kortleve
DHDora Hammerl
Dora Hammerl
MBMandy van Brakel
Mandy van Brakel
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
Triple-negative breast cancer (TNBC) has an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. Human leukocyte antigen-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCR) from naïve repertoires. Following gene introduction into T cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize noncognate epitopes from alternative source proteins. Notably, this TCR-mediated killing of three-dimensional (3D) tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T cells as a treatment for the vast majority of patients with TNBC. Significance: Metastatic TNBC has a dismal prognosis. This study discovers Ropporin-1 as a target for T-cell therapy for most patients. The selected TCR is highly specific and sensitive in advanced models, and preclinical testing shows that the T-cell product expressing this TCR, manufactured according to good manufacturing practice, has favorable safety and potency.

26 February 2025 in Cancer Research
Verified
Journal Article
Open access
ASAnn Seynhaeve
Ann Seynhaeve
HLHui Liu
Hui Liu
MPMarjolein Priester
Marjolein Priester
MVMike Valentijn
Mike Valentijn
CHConny van Holten-Neelen
Conny van Holten-Neelen
THTimo L. M. Ten Hagen
Timo L. M. Ten Hagen
TNFα induces vascular permeability and plays an important role in inflammation. In addition, TNFα-induced vascular leakage is involved in the increased extravasation of nanoparticle-formulated chemotherapeutic drugs, improving drug delivery and subsequent tumor response. In this study, we uncovered a positive correlation between the presence of pericytes in the tumor-associated vasculature and TNFα-induced leakage and drug delivery, especially when drugs were encapsulated in nanoparticles. RNA sequencing and pathway analysis identified high expression of C-X-C motif chemokine ligand 10 (CXCL10) in TNFα-stimulated pericytes. In addition, TNFα increased CXCL10 protein production by pericytes in vitro. In animal studies, tumor types with vessels with high pericyte coverage showed enhanced permeability and extravasation of drugs encapsulated in nanoparticles following treatment with TNFα, which could be blocked with a CXCL10-neutralizing antibody. In contrast, tumors harboring vessels with low pericyte numbers did not display increased drug extravasation in response to TNFα. Lack of pericyte coverage could be compensated by coadministration of CXCL10. These findings reveal a mechanism by which TNFα induces CXCL10 release from pericytes, resulting in increased endothelial permeability, vascular leakage, and drug delivery. Significance: TNFα stimulates tumor-associated pericytes to produce CXCL10 that mediates vascular leakage and assists in the intratumoral delivery of nanoparticle-encapsulated chemotherapeutic drugs.

1 January 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
ZCZiyun Cheng
Ziyun Cheng
MAMohamadreza Amin
Mohamadreza Amin
MBMandy van Brakel
Mandy van Brakel
ASAndrea Sacchetti
Andrea Sacchetti
RKRobbert Q Kim
Robbert Q Kim
THTimo L. M. Ten Hagen
Timo L. M. Ten Hagen
Purpose: Anti-programmed death ligand-1 monoclonal antibody (anti-PD-L1 mAb) therapy has demonstrated notable clinical success. However, efficacy is often limited by transient interactions at the tumor-immune interface, limiting sustained immune activation. To address this, we hypothesized that liposomal delivery of anti-PD-L1 mAbs could enhance therapeutic efficacy. Nanosystems may increase binding avidity and prolong cell-surface retention, and enable multivalent antibody presentation through conjugation of multiple antibodies onto a single liposome. Methods: In this study, we engineered multivalent anti-PD-L1 liposomes (anti-PD-L1 LPs) by conjugating FDA-approved anti-PD-L1 mAbs (atezolizumab) at varying densities onto a clinically relevant liposomal formulation. The biophysical properties, cellular interactions, and therapeutic potential of anti-PD-L1 LPs were evaluated using two melanoma cell line models (BLM and MZ2Mel43), employing multiple analytical techniques. Results: Our results demonstrated that high-density anti-PD-L1 LPs exhibited superior binding avidity, prolonged membrane retention, and reduced non-specific cellular interaction with PD-L1-expressing cells compared to both low-density and non-targeted LPs. Additionally, in 3D tumor spheroid models, high-density anti-PD-L1 LPs showed deeper penetration, suggesting improved tissue accessibility compared with low-density formulations. Moreover, compared to free antibodies, anti-PD-L1 LPs displayed a higher association rate (k_on) and a significantly lower dissociation rate (k_off), resulting in an overall improved (lower) dissociation constant (K_D). Functional assays confirmed that anti-PD-L1 LPs achieved superior PD-L1 blockade compared to free antibodies. Importantly, in co-cultures of human peripheral blood mononuclear cells and tumor cells, anti-PD-L1 LPs maintained immunomodulatory activity comparable to free anti-PD-L1 antibodies. Conclusion: This study highlights the critical role of ligand density in enhancing binding strength, tumor retention, and tissue penetration of the anti-PD-L1 LP system. Our nanosystem offers a promising improvement over conventional anti-PD-L1 mAbs, supporting the broader application of this modular liposomal platform to other therapeutic antibodies in melanoma and other solid tumors. Plain Language Summary: Current limitations and our approach Cancer immunotherapy drugs like anti-PD-L1 antibodies help the immune system fight cancer, but they often do not stay in tumors long enough to work effectively. To improve this, we developed nanoscale lipid-based carriers, like tiny fat bubbles (called liposomes) densely coated with anti-PD-L1 antibodies. These engineered liposomes bind to tumors more effectively, stay longer, and deliver treatment more precisely than regular antibodies. Key discoveries We discovered that packing more drugs onto each tiny carrier makes them stick to tumors better and last longer. Also, how we deliver these drugs matters too—the carrier-delivered versions bind to tumors more effectively than regular antibody drugs. Importantly, in controlled lab tests with cells, these engineered antibodies work just as powerfully as regular immunotherapy—proving we have created a delivery system without sacrificing cancer-fighting strength. Conclusion and potential benefits This research introduces an innovative approach to cancer immunotherapy delivery using antibody-coated liposomes. By enhancing tumor targeting and retention while minimizing accumulation in healthy tissues, this method could improve treatment effectiveness while reducing side effects. The platform offers three key advantages: patients may require fewer treatment sessions with more durable results, clinicians gain enhanced options for treating melanoma and solid tumors, and researchers can extend this adaptable platform to other cancer therapies. Future directions Our immediate focus will be on validating these findings in animal models and expanding the technology to other immunotherapies. The use of clinically approved components positions this approach for potential rapid translation to human trials, pending successful preclinical results.

15 October 2025 in bioRxiv
Verified
Preprint
Open access
AMAlexandre Marraffa
Alexandre Marraffa
CBCor Berrevoets
Cor Berrevoets
MMMargherita Mosiello
Margherita Mosiello
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules. We observed that TCRs coupled to ICOS mediated exceptionally long-term responses including delay of tumor recurrence and cures in a mouse tumor model. TCR:ICOS T cells showed enhanced and antigen-specific production of inflammatory cytokines and resistance to exhaustion. Genetic ablation of ICOS-mediated activation of the PI3K-NFκB pathway neutralized the long-term anti-tumor effects. To translate TCR:ICOS to human T cells, we identified a single amino acid change in the cytosolic tail which was necessary for functional surface expression. Notably, the optimized receptor sustained performance of human T cells upon repeated stimulation across multiple antigen specificities. Collectively, we present a novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy. Highlights: Newly designed co-stimulatory TCR, with extracellular TCR-V and C domains coupled to CD28 transmembrane domain, and ICOS and CD3ε intracellular domains (in short TCR:ICOS) provides: ➢ durable anti-tumor response and T cell persistence in mouse model ➢ inflammatory T cell phenotype and resistance to T cell exhaustion ➢ effects via PI3K and NFκB activation ➢ translation to human T cells upon single amino acid mutation in TCR:ICOS tail ➢ extension to multiple clinically relevant TCRs while preserving prolonged T cell fitness Abstract Figure:

17 June 2026
Verified
Other
Open access
DKDian Kortleve
Dian Kortleve
DHDora Hammerl
Dora Hammerl
MBMandy van Brakel
Mandy van Brakel
RWRebecca Wijers
Rebecca Wijers
DRDaphne Roelofs
Daphne Roelofs
RDReno Debets
Reno Debets
FLY-1A TCR T-cells do not recognize ROPN1-negative and/or HLA-A2-negative tumor cells.